Urinary Proteomic Biomarkers for Diagnosis and Risk Stratification of Autosomal Dominant Polycystic Kidney Disease: A Multicentric Study

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Kistler, Andreas D ^a   Serra, Andreas L ^a   Siwy, Justyna ^b   Poster, Diane ^a   Krauer, Fabienne ^a   Torres, Vicente E ^c   Mrug, Michal ^d,e   Grantham, Jared J ^f   Bae, Kyongtae T ^g   Bost, James E ^g,h   Mullen, William ⁱ   Wüthrich, Rudolf P ^a   Mischak, Harald ^b,i   Chapman, Arlene B ^j  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^c MAYO CLINIC   (United States)

^d University of Alabama at Birmingham   (United States)

^e BIRMINGHAM VA MEDICAL CENTER   (United States)

^f UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h BOOZ ALLEN HAMILTON   (United States)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENOTYPE; HUMAN; INTERMETHOD COMPARISON; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; URINALYSIS;

ADULT; BIOLOGICAL MARKERS; ELECTROPHORESIS, CAPILLARY; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROGNOSIS; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84872243596     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053016     Document Type: Article

References (55)

1. Dalgaard OZ, (1957) Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families. Acta Med Scand (Suppl 328) pp. 1-255.
2. Iglesias CG, Torres VE, Offord KP, Holley KE, Beard CM, et al. (1983) Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935-1980. Am J Kidney Dis 2: 630-639.
3. Hateboer N, v Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, et al. (1999) Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 353: 103-107.
4. Harris PC, Rossetti S, (2010) Determinants of renal disease variability in ADPKD. Adv Chronic Kidney Dis 17: 131-139.
5. Chapman AB, Johnson AM, Gabow PA, Schrier RW, (1994) Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5: 1349-1354.
6. Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, et al. (1992) Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 41: 1311-1319.
7. Johnson AM, Gabow PA, (1997) Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol 8: 1560-1567.
8. Torres VE, Harris PC, Pirson Y, (2007) Autosomal dominant polycystic kidney disease. Lancet 369: 1287-1301.
9. Wuthrich RP, Serra AL, Kistler AD, (2009) Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy. Kidney Blood Press Res 32: 380-387.
10. Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, et al. (2009) Unified Criteria for Ultrasonographic Diagnosis of ADPKD. J Am Soc Nephrol 20: 205-212.
11. Harris PC, Rossetti S, (2010) Molecular diagnostics for autosomal dominant polycystic kidney disease. Nat Rev Nephrol 6: 197-206.
12. Fliser D, Novak J, Thongboonkerd V, Argiles A, Jankowski V, et al. (2007) Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol 18: 1057-1071.
13. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, et al. (2006) Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 7: 230-240.
14. Siwy J, Mullen W, Golovko I, Franke J, Zurbig P, (2011) Human urinary peptide database for multiple disease biomarker discovery. Proteomics Clin Appl 5: 367-374.
15. Alkhalaf A, Zurbig P, Bakker SJ, Bilo HJ, Cerna M, et al. (2010) Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One 5: e13421.
16. Snell-Bergeon JK, Maahs DM, Ogden LG, Kinney GL, Hokanson JE, et al. (2009) Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. Diabetes Technol Ther 11: 1-9.
17. Zurbig P, Jerums G, Hovind P, Macisaac R, Mischak H, et al. (2012) Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy. Diabetes.
18. Kistler AD, Mischak H, Poster D, Dakna M, Wuthrich RP, et al. (2009) Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int 76: 89-96.
19. Grantham JJ, Chapman AB, Torres VE, (2006) Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 1: 148-157.
20. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, et al. (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363: 820-829.
21. Weimbs T, (2007) Polycystic kidney disease and renal injury repair: common pathways, fluid flow, and the function of polycystin-1. Am J Physiol Renal Physiol 293: F1423-1432.
22. Bolignano D, Coppolino G, Campo S, Aloisi C, Nicocia G, et al. (2007) Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease. Am J Nephrol 27: 373-378.
23. Kuehn EW, Hirt MN, John AK, Muehlenhardt P, Boehlke C, et al. (2007) Kidney injury molecule 1 (Kim1) is a novel ciliary molecule and interactor of polycystin 2. Biochem Biophys Res Commun 364: 861-866.
24. Meijer E, Boertien WE, Nauta FL, Bakker SJ, van Oeveren W, et al. (2010) Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Am J Kidney Dis 56: 883-895.
25. Metzger J, Kirsch T, Schiffer E, Ulger P, Mentes E, et al. (2010) Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney Int.
26. Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, et al. (2012) Kidney Volume and Functional Outcomes in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol.
27. Chalmers MJ, Mackay CL, Hendrickson CL, Wittke S, Walden M, et al. (2005) Combined top-down and bottom-up mass spectrometric approach to characterization of biomarkers for renal disease. Anal Chem 77: 7163-7171.
28. Mischak H, Coon JJ, Novak J, Weissinger EM, Schanstra JP, et al. (2009) Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom Rev 28: 703-724.
29. Mangos S, Lam PY, Zhao A, Liu Y, Mudumana S, et al. (2010) The ADPKD genes pkd1a/b and pkd2 regulate extracellular matrix formation. Dis Model Mech 3: 354-365.
30. Mrug M, Zhou J, Woo Y, Cui X, Szalai AJ, et al. (2008) Overexpression of innate immune response genes in a model of recessive polycystic kidney disease. Kidney Int 73: 63-76.
31. Schieren G, Rumberger B, Klein M, Kreutz C, Wilpert J, et al. (2006) Gene profiling of polycystic kidneys. Nephrol Dial Transplant 21: 1816-1824.
32. Therezo A, Bacchi C, Franco M, (1998) Histogenesis of the cysts in the autosomal dominant polycystic kidney disease- An immunohistochemical study. Applied Immunohistochemistry 6: 219-223.
33. Cowley BD Jr, Ricardo SD, Nagao S, Diamond JR, (2001) Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats. Kidney Int 60: 2087-2096.
34. Zheng D, Wolfe M, Cowley BD Jr, Wallace DP, Yamaguchi T, et al. (2003) Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 14: 2588-2595.
35. Meijer E, Bakker SJ, van der Jagt EJ, Navis G, de Jong PE, et al. (2011) Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6: 361-368.
36. Parikh CR, Dahl NK, Chapman AB, Bost JE, Edelstein CL, et al. (2012) Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int.
37. Gronwald W, Klein MS, Zeltner R, Schulze BD, Reinhold SW, et al. (2011) Detection of autosomal dominant polycystic kidney disease by NMR spectroscopic fingerprinting of urine. Kidney Int 79: 1244-1253.
38. Serra AL, Kistler AD, Poster D, Struker M, Wuthrich RP, et al. (2007) Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrology 8: 13.
39. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, et al. (2010) Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease. N Engl J Med pp. NEJMoa0907419.
40. Kistler AD, Poster D, Krauer F, Weishaupt D, Raina S, et al. (2009) Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 75: 235-241.
41. Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, et al. (2003) Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 64: 1035-1045.
42. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, et al. (2006) Volume Progression in Polycystic Kidney Disease. N Engl J Med 354: 2122-2130.
43. Delles C, Schiffer E, von Zur Muhlen C, Peter K, Rossing P, et al. (2010) Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J Hypertens 28: 2316-2322.
44. Haubitz M, Good DM, Woywodt A, Haller H, Rupprecht H, et al. (2009) Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics 8: 2296-2307.
45. Schiffer E, Vlahou A, Petrolekas A, Stravodimos K, Tauber R, et al. (2009) Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res 15: 4935-4943.
46. Good DM, Zurbig P, Argiles A, Bauer HW, Behrens G, et al. (2010) Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 9: 2424-2437.
47. Drube J, Schiffer E, Mischak H, Kemper MJ, Neuhaus T, et al. (2009) Urinary proteome pattern in children with renal Fanconi syndrome. Nephrol Dial Transplant 24: 2161-2169.
48. Kistler AD, Mischak H, Poster D, Dakna M, Wuthrich RP, et al. (2009) Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int.
49. Neuhoff N, Kaiser T, Wittke S, Krebs R, Pitt A, et al. (2004) Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom 18: 149-156.
50. Theodorescu D, Fliser D, Wittke S, Mischak H, Krebs R, et al. (2005) Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis 26: 2797-2808.
51. Coon J, Zurbig P, Dakna M, Dominiczak A, Decramer S, et al. (2008) CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl in press.
52. Reiner A, Yekutieli D, Benjamini Y, (2003) Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19: 368-375.
53. Decramer S, Wittke S, Mischak H, Zurbig P, Walden M, et al. (2006) Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat Med 12: 398-400.
54. Mischak H, Vlahou A, Ioannidis JP, (2012) Technical aspects and inter-laboratory variability in native peptide profiling: The CE-MS experience. Clin Biochem.
55. Zurbig P, Renfrow MB, Schiffer E, Novak J, Walden M, et al. (2006) Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis 27: 2111-2125.